# Omnicell, Inc. (OMCL)

> Source: Nexqual · https://nexqual.com/OMCL · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Omnicell, Inc. (OMCL), nexqual.com/OMCL" · informational, not investment advice.

**Price:** USD 35.95 (+1.58% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 35.39 · day 35.23–36.23 · 52w 29.09–55 · market cap $1.63B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $1.25B, net income $39.1M (3.1% margin), free cash flow $143M (SEC filings).
- Valuation: P/E 41.8x (avg 593.9x at the last 2 fiscal year-ends).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (8 analysts), mean target USD 57.86 (range 45–70).
- Total return with dividends: 1Y +18.6% vs S&P 500 +18.1%; 5Y -77.2% vs S&P 500 +85.1%.
- Next earnings: 2026-10-29, EPS estimate USD 0.42, revenue estimate $304M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.13B | $1.30B | $1.15B | $1.11B | $1.18B | $1.25B |
| Gross profit | $555M | $589M | $497M | $471M | $503M | — |
| Operating income | $89.5M | -$2.3M | -$34.9M | $337K | $5.2M | $58.0M |
| Net income | $77.8M | $5.6M | -$20.4M | $12.5M | $2.1M | $39.1M |
| EPS (diluted) | $1.62 | $0.12 | -$0.45 | $0.27 | $0.04 | — |
| Free cash flow | $203M | $30.2M | $140M | $151M | $86.9M | $143M |
| Gross margin | 49.0% | 45.4% | 43.3% | 42.3% | 42.5% | — |
| Operating margin | 7.9% | -0.2% | -3.0% | 0.0% | 0.4% | 4.6% |
| Net margin | 6.9% | 0.4% | -1.8% | 1.1% | 0.2% | 3.1% |
| Revenue growth | +26.9% | +14.5% | -11.5% | -3.0% | +6.5% | — |
| Cash + short-term investments | $349M | $330M | $468M | $369M | $197M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 41.8x · P/S 1.3x · P/FCF 11.5x · P/B 1.3x · FCF yield 8.72% · Earnings yield 2.39%
P/E at fiscal year-ends: Dec 2025 1023.5x, Dec 2024 164.3x.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 8 analysts; mean target USD 57.86 (low 45, high 70).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-03 | Piper Sandler | Target lowered | Overweight | $55 → $45 |
| 2026-07-31 | Wells Fargo | Target lowered | Overweight | $55 → $50 |
| 2026-07-31 | Keybanc | Target lowered | Overweight | $70 → $65 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | +18.6% | -77.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +18.7% | -25.6% |
| Volatility (annualized) | 50.1% | 48.5% |
| Max drawdown | -37.3% (Jan 2026→Sep 2026) | -85.9% (Nov 2021→May 2025) |

## Peers (Health Information Services)
CERT (Certara, Inc.) USD 9.66 +0.63% · SDGR (Schrodinger, Inc.) USD 25.48 -1.58% · GDRX (GoodRx Holdings, Inc.) USD 3.51 +1.59% · OMDA (Omada Health, Inc.) USD 18.67 +2.02% · TDOC (Teladoc Health, Inc.) USD 5.97 -0.50% · HSTM (HealthStream, Inc.) USD 33.75 +0.00%

## More
Full page: https://nexqual.com/OMCL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt